Difference between revisions of "Team:NUDT CHINA/Design"

Line 390: Line 390:
  
  
 +
<h1>
 +
<span><span style="color:#ff1015">PAGE STILL UNDER CONSTRUCTION</span></span>
 +
</h1>
  
  
 
 
<br/><br/><br/>NUDT_CHINA: This page is under construction.<br/><br/><br/>
+
<h2>
 
+
<span><span style="color:#7f1015">General Design</span></span><hr />
 +
</h2>
 +
<p style="text-indent:22pt;">
 +
<span style="line-height:2;font-family:Perpetua;font-size:18px;">To develop a novel cell-free platform for
 +
the low-cost, high-efficient and visualized detection of serum miRNAs, two
 +
essential systems, namely RCA based DNA amplification system, and dCas9
 +
conjugated split-reporting system, were combined, modified, and then assessed
 +
in our project.</span><span style="line-height:2;font-family:Perpetua;font-size:18px;">&nbsp; </span>
 +
</p>
 +
<p style="text-indent:22pt;">
 +
<span style="line-height:2;font-family:Perpetua;font-size:18px;">The first system, RCA based DNA
 +
amplification system, was introduced to primarily amplify the input miRNA
 +
signal with a high specificity under an isothermal and moderate condition.
 +
Specifically, a dumbbell shaped probe containing a tunable toehold domain on
 +
its loop was custom designed and prepared for the detection of a specific
 +
target miRNA. Target miRNAs could bind with the toehold domain, and then
 +
trigger the toehold-mediated strand displacement (TMSD) process resulting in a
 +
switch of the probe from the dumbbell shaped form into a circular form (termed
 +
as initiated probe, or iprobe in brief). The iprobe could then be used as the
 +
template for the subsequent RCA reaction (Figure 1, left panel). A mismatched
 +
miRNA, however, would fail to trigger the TMSD due to the resistance of the
 +
stabilized dumbbell structure, thus producing no amplification products. Once
 +
RCA products were produced, a traditional Sybr I based fluorescence assay could
 +
be conducted to assess the effectiveness of RCA based DNA amplification system.
 +
A fluoresce microplate reader would be needed for such matters (Figure 1,
 +
middle panel). </span>
 +
</p>
 +
<p style="text-indent:22pt;">
 +
<span style="line-height:2;font-family:Perpetua;font-size:18px;">&nbsp;</span>
 +
</p>
 +
<p align="center" style="text-align:center;text-indent:22.1pt;">
 +
<b><span style="line-height:2;font-family:Perpetua;font-size:18px;">(Figure 1)</span></b>
 +
</p>
 +
<p align="center" style="text-align:center;text-indent:22.1pt;">
 +
<b><span style="line-height:2;font-family:Perpetua;font-size:18px;">&nbsp;</span></b>
 +
</p>
 +
<p style="text-indent:22pt;">
 +
<span style="line-height:2;font-family:Perpetua;font-size:18px;">In order to achieve the further
 +
amplification and visualization of the RCA output signal, the dCas9 conjugated
 +
split-reporting system was then introduced into our scheme. The fusion proteins
 +
of dCas9 and split-HRP fragments, namely sHRP-N-dCas9 (N-sHdC) and sHRP-C-dCas9
 +
(C-sHdC) could be obtained from genetically modified </span><i><span style="line-height:2;font-family:Perpetua;font-size:18px;">E. coli</span></i><span style="line-height:2;font-family:Perpetua;font-size:18px;"> strains containing relevant expression plasmids. With the
 +
guidance of sgRNA, N-sHdC proteins and C-sHdC proteins would be able to bind
 +
randomly to the numerous double-strand loci on the RCA product (Figure 2, right
 +
panel). For all those bound to loci that were close enough, split-HRP fragments
 +
would interact with each other and HRP enzyme activity would be retained.
 +
Building on this, HRP enzyme activity could then be determined by adding
 +
substrates such as 3,3',5,5'-Tetramethylbenzidine (TMB) with a visual output
 +
signal.</span>
 +
</p>
 +
<p style="text-indent:22pt;">
 +
<span style="line-height:2;font-family:Perpetua;font-size:18px;">&nbsp;</span>
 +
</p>
 +
<p align="center" style="text-align:center;text-indent:22.1pt;">
 +
<b><span style="line-height:2;font-family:Perpetua;font-size:18px;">(Figure 2)</span></b>
 +
</p>
 +
<p align="center" style="text-align:center;text-indent:22.1pt;">
 +
<b><span style="line-height:2;font-family:Perpetua;font-size:18px;">&nbsp;</span></b>
 +
</p>
 +
<p style="text-indent:22pt;">
 +
<span style="line-height:2;font-family:Perpetua;font-size:18px;">Since most proteins could remain stable
 +
under normal storage conditions if freeze dried, and retain their activity
 +
after rehydrated. Our system could then be developed into a kit that contains
 +
freeze-dried components together with other liquid components that is stable in
 +
regular storage conditions, such as TMB substrate and DEPC treated water (Figure
 +
2, upper and middle panel). Meanwhile, with its advantage in visualized outputs
 +
and moderate temperature (37</span><span style="line-height:2;font-family:Perpetua;font-size:18px;">℃</span><span style="line-height:2;font-family:Perpetua;font-size:18px;">) detection process, such
 +
kit would be able to be deployed in low-resource settings and dramatically
 +
lower the cost of and technical barrier for wider cancer scanning and early
 +
detection.</span>
 +
</p>
 +
<p style="text-indent:22pt;">
 +
<span style="line-height:2;font-family:Perpetua;font-size:18px;">&nbsp;</span>
 +
</p>
 +
<h2>
 +
<span><span style="color:#7f1015">Prototype: serum let-7a detection system</span></span><hr />
 +
</h2>
 +
<p style="text-indent:22pt;">
 +
<span style="line-height:2;font-family:Perpetua;font-size:18px;">To validate and demonstrate our design, miR
 +
let-7a, as an important serum biomarker for non-small cell lung cancer, was
 +
chosen as the target miRNA. Previously, miR let-7a has been reported to be
 +
down-regulated for 20%-40% in serum samples from NSCLC patients compared to
 +
healthy people </span><sup><span style="line-height:2;font-family:Perpetua;font-size:18px;">1</span></sup><span style="line-height:2;font-family:Perpetua;font-size:18px;">.</span>
 +
</p>
 +
<p style="text-indent:22pt;">
 +
<span style="line-height:2;font-family:Perpetua;font-size:18px;">To produce miR let-7a for further detection,
 +
we put the sequence of let-7a under control of a T7 promoter. The plasmid was
 +
linearized at the point right after let-7a sequence and </span><i><span style="line-height:2;font-family:Perpetua;font-size:18px;">in vitro</span></i><span style="line-height:2;font-family:Perpetua;font-size:18px;"> transcription kit was then used for the transcription of
 +
let-7a.</span>
 +
</p>
 +
<p style="text-indent:22pt;">
 +
<span style="line-height:2;font-family:Perpetua;font-size:18px;">AS A PROOF OF CONCEPT, let-7a was diluted in
 +
DEPC-treated water on various concentrations to assess the reliability, sensibility
 +
and specificity of our scheme. To begin with, four different probes were
 +
designed to be probe candidates for the RCA reaction based on let7a sequence
 +
and probe design principles. Once they have been synthesized and purified, RCA
 +
reactions with 10nM let-7a input were performed against all four probes to
 +
select the optimal probe for further test. By using this probe, the sensibility
 +
and specificity of RCA reaction were then determined with sybr I fluorescence
 +
assay. Moreover, N-sHdC and C-sHdC protein were expressed and purified from </span><i><span style="line-height:2;font-family:Perpetua;font-size:18px;">E.coli</span></i><span style="line-height:2;font-family:Perpetua;font-size:18px;">, and subsequently used for the
 +
dCas9 binding process together with an </span><i><span style="line-height:2;font-family:Perpetua;font-size:18px;">in
 +
vitro</span></i><span style="line-height:2;font-family:Perpetua;font-size:18px;"> expressed sgRNA. TMB substrate was used to test the HRP activity.
 +
(See proof of concept page for more details)</span>
 +
</p>
 +
<p style="text-indent:22pt;">
 +
<span style="line-height:2;font-family:Perpetua;font-size:18px;">FOR FURTHER DEMONSTRATION OF OUR PROJECT, let-7a
 +
was dissolved in 7% mixed human serum collected from 50 healthy volunteers.
 +
Similarly, sybr I fluorescence assay and HRP activity assay was conducted to
 +
verify the reliability, sensibility and specificity of our scheme in stimulated
 +
clinical samples. MOREOVER, serum samples collected from NSCLC patients and
 +
healthy volunteers were also tested after different pretreatment for further
 +
demonstration of our scheme. (See demonstration page for more details)</span>
 +
</p>
 +
<p>
 +
<span style="line-height:2;font-family:Perpetua;font-size:18px;">&nbsp;</span>
 +
</p>
 +
<h2>
 +
<span><span style="color:#7f1015">Reference</span></span><hr />
 +
</h2>
 +
<p style="text-indent:-0.55pt;">
 +
<span style="line-height:2;font-family:Perpetua;font-size:18px;">1</span><span style="line-height:2;font-family:Perpetua;font-size:18px;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="line-height:2;font-family:Perpetua;font-size:18px;">Jeong, H. C.</span><i><span style="line-height:2;font-family:Perpetua;font-size:18px;"> et al.</span></i><span style="line-height:2;font-family:Perpetua;font-size:18px;"> Aberrant expression of let-7a miRNA in the blood of
 +
non-small cell lung cancer patients. </span><i><span style="line-height:2;font-family:Perpetua;font-size:18px;">Mol
 +
Med Rep</span></i><span> </span><b><span style="line-height:2;font-family:Perpetua;font-size:18px;">4</span></b><span style="line-height:2;font-family:Perpetua;font-size:18px;">, 383-387,
 +
doi:10.3892/mmr.2011.430 (2011).</span>
 +
</p>
 +
<p style="text-indent:22pt;">
 +
<span style="line-height:2;font-family:Perpetua;font-size:18px;">&nbsp;</span>
 +
</p>
  
  

Revision as of 18:28, 14 October 2016

NUDT_CHINA 2016